Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2002 Apr 10;16(3):146–150. doi: 10.1002/jcla.10032

Correlation of p21 gene codon 31 polymorphism and TNF‐α gene polymorphism with nasopharyngeal carcinoma

Ming‐Hsui Tsai 1, Wen‐Chi Chen 2,3, Fuu‐Jen Tsai 2,4,✉
PMCID: PMC6808169  PMID: 11968052

Abstract

Background p21 (WAF1/CIP1) is a downstream protein from p53 and can arrest the cell cycle at the G1/S phase in response to signal from p53. The most frequently seen polymorphic site is at codon 31, where a base change from AGC to AGA causes an amino acid change from serine to arginine. Tumor necrosis factor‐alpha (TNF‐α) is a cytokine that is secreted from macrophages, and is related to a sequence of events in the response to inflammation and cancer formation. The TNF‐α gene promoter –308 G/A polymorphism has been reported to be associated with some cancers. In this study, these polymorphisms were proposed to be a candidate genetic marker of nasopharyngeal carcinoma (NPC). The distribution was analyzed in 47 NPC patients and a control group of 119 healthy people. The association of the p21 codon 31 polymorphism with NPC was detected by polymerase chain reaction (PCR) and restriction analysis by Blp I endonuclease, and calculated by the chi‐square test. The TNF‐α gene promoter –308 G/A polymorphism was identified by Nco I endonuclease. The distribution of the gene p21 codon 31 polymorphisms showed no significant difference between the two groups. The serine form of p21 codon 31 was more prominent in smokers than nonsmokers among the NPC patients (P < 0.05). There was no significant difference in the distribution of TNF‐α gene promoter –308 G/A polymorphism between control and cancer patients. The results indicate that the gene p21 codon 31 polymorphism and TNF‐α promoter –308 polymorphism are not correlated with NPC. However, the difference between smokers and nonsmokers suggests that an environmental factor may be involved in association with the p21 gene in the formation of NPC. J. Clin. Lab. Anal. 16:146–150, 2002. © 2002 Wiley‐Liss, Inc.

Keywords: nasopharyngeal carcinoma, NPC, genetic polymorphism, p21 gene

REFERENCES

  • 1. Hildesheim A, Levine PH. 1993. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev 15:466–485. [DOI] [PubMed] [Google Scholar]
  • 2. Sun Y, Nakamura K, Wendel E, Colburn N. 1993. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor‐suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 90:2827–2831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Sun Y, Hegamyer G, Colburn NH. 1993. Nasopharyngeal carcinoma shows no detectable retinoblastoma gene alterations. Oncogene 8:791–795. [PubMed] [Google Scholar]
  • 4. NIH/CEPH Collaborative Mapping Group . 1992. A comprehensive genetic linkage map of the human genome. Science 258:67–86. [PubMed] [Google Scholar]
  • 5. Lorder N. 1999. Genetic variations can point the way to disease gene. Nature 401:734. [DOI] [PubMed] [Google Scholar]
  • 6. el‐Deiry WS, Tokino T, Waldman T, et al. 1995. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55:2910–2914. [PubMed] [Google Scholar]
  • 7. Zhang H, Xiong Y, Beach D. 1993. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinases complexes. Mol Biol Cell 4:897–906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Xiong Y, Zhang H, Beach D. 1992. D type cyclins associated with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505–514. [DOI] [PubMed] [Google Scholar]
  • 9. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704. [DOI] [PubMed] [Google Scholar]
  • 10. Koopmann J, Maintz D, Schild S, et al. 1995. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumors. Br J Cancer 72:1230–1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Li YJ, Laurent‐Puig P, Salmon RJ, Thomas G, Hamelin R. 1995. Polymorphisms and probable lack of mutation in the WAF1‐CIP1 gene in colorectal cancer. Oncogene 10:599–601. [PubMed] [Google Scholar]
  • 12. Bahl R, Arora S, Nath N, Mathur M, Shukla NK, Ralhan R. 2000. Novel polymorphism in p21 waf1/cip1 cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene 19:323–328. [DOI] [PubMed] [Google Scholar]
  • 13. Rossler K, Suchanek G, Breitschopf H, et al. 1995. Detection of tumor necrosis factor‐alpha protein and messenger RNA in human glial brain tumors. Comparison of immunohistochemistry with in situ hybridization using molecular probes. J Neurosurg 83:291–297. [DOI] [PubMed] [Google Scholar]
  • 14. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. 2000. Tumor necrosis factor‐alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 164:800–805. [DOI] [PubMed] [Google Scholar]
  • 15. deMiguel MP, Royuela M, Bethencourt FR, Santamaria L, Fraile B, Paniagua R. 2000. Immunoexpression of tumor necrosis factor‐alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplastic and carcinomatous human prostate. Cytokine 12:535–538. [DOI] [PubMed] [Google Scholar]
  • 16. Wilson AG, Giovane FS di, Blakemore AIF, Duff GW. 1992. Single base polymorphism in the human tumor necrosis factor alpha (TNF‐α) gene detectable by Nco I restriction of PCR product. Hum Mol Genet 1:353. [DOI] [PubMed] [Google Scholar]
  • 17. Galbraith GMP, Pandey JP. 1995. Tumor necrosis factor alpha (TNF‐α) gene polymorphism in alopecia areata. Hum Genet 96:433–436. [DOI] [PubMed] [Google Scholar]
  • 18. Sun Y, Hildesheim A, Li H, et al. 1995. No point mutation but a codon 31 ser→arg polymorphism of the WAF‐1/CIP‐1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomark Prev 4:261–267. [PubMed] [Google Scholar]
  • 19. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. 2000. Lack of evidence of association pf p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 91:9–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Vogelstein B, Fearon ER, Kern SE, et al. 1989. Allelotype of colorectal carcinomas. Science 244:207–211. [DOI] [PubMed] [Google Scholar]
  • 21. Lukeis R, Irving L, Garson M, Hasthorpe S. 1990. Cytogenetics of non‐small cell lung cancer: analysis of consistent non‐random abnormalities. Gen Chrom Cancer 2:116–124. [DOI] [PubMed] [Google Scholar]
  • 22. Morita R, Ishikawa J, Tsutsumi M, et al. 1991. Allelotype of renal cell carcinoma. Cancer Res 51:820–823. [PubMed] [Google Scholar]
  • 23. Sato T, Salto H, Morita R, Koi S, Lee JH, Nakamura Y. 1991. Allelotype of human ovarian cancer. Cancer Res 51:5118–5122. [PubMed] [Google Scholar]
  • 24. Lin CS, Kuo HH, Chen JY, Yang CS, Wang WB. 2000. Epstein‐Barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post‐translationally. J Mol Biol 303:7–23. [DOI] [PubMed] [Google Scholar]
  • 25. Brenner DA, O’Hara M, Angel P, Chojkier M, Karin M. 1999. Prolonged activation of JUN and collagenase genes by tumour necrosis factor‐alpha. Nature 337:661–663. [DOI] [PubMed] [Google Scholar]
  • 26. Honchel R, McDonnell S, Schaid DJ, Thibodeau SN. 1996. Tumor necrosis factor‐alpha allelic frequency and chromosome 6 allelic imbalance in patients with colorectal cancer. Cancer Res 56:145–149. [PubMed] [Google Scholar]
  • 27. Mann EA, Hibbs MS, Spiro JD, et al. 1995. Cytokine regulation of gelatinase production by head and neck squamous cell carcinoma; the role of tumor necrosis factor‐alpha. Ann Otol Rhinol Laryngol 104:203–209. [DOI] [PubMed] [Google Scholar]
  • 28. Okamaoto M, Oyasu R. 1997. Transformation in vitro of a nontumorigenic rat urothelial cell line by tumor necrosis factor‐alpha. Lab Invest 77:139–144. [PubMed] [Google Scholar]
  • 29. Hawrami K, Hitman GA, Rema M, et al. 1996. An association in non‐insulin‐dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism. Hum Immunol 46:49–54. [DOI] [PubMed] [Google Scholar]
  • 30. Wingerchuck D, Liu Q, Sobell J, Sommer S, Weinshenker BG. 1997. A population‐based case‐control study of the tumor necrosis factor alpha‐308 polymorphism in multiple sclerosis. Neurology 49:626–628. [DOI] [PubMed] [Google Scholar]
  • 31. Kroeger KM, Carville KS, Abraham LJ. 1997. The –308 tumor necrosis factor‐alpha promoter polymorphism effects transcription. Mol Immunol 34:391–399. [DOI] [PubMed] [Google Scholar]
  • 32. Warzocha K, Ribero P, Bienvenu J, et al. 1998. Genetic polymorphisms in the tumor necrosis factor locus influence non‐Hodgkin’s lymphoma outcome. Blood 91:3574–3581. [PubMed] [Google Scholar]
  • 33. Park KS, Mok JW, Rho SA, Kim JC. 1998. Analysis of TNFB and TNFA NcoI RFLP in colorectal cancer. Mol Cells 8:246–249. [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES